# Overview by chatgpt

The current evidence for **CLPTM1 (not CLPTM1L)** suggests that it is a biologically interesting candidate for neurological disease, particularly epilepsy, but its status as a Mendelian disease gene remains unestablished.

There are several findings worth distinguishing, especially if you are evaluating rare variants or interpreting exome/genome sequencing data.

## 1. Gene identity and biological function

**CLPTM1** (Cleft Lip and Palate Transmembrane Protein 1) is located on chromosome **19q13.32**.

Its best-characterised function is the regulation of GABA\(_A\) receptor trafficking.

In particular:
- CLPTM1 interacts with GABA\(_A\) receptor subunits.
- It retains a proportion of these receptors in the endoplasmic reticulum.
- It regulates the number of GABA\(_A\) receptors reaching the neuronal cell surface.
- Consequently, it influences inhibitory neurotransmission.

This is an interesting disease mechanism because altered GABAergic signalling can affect neuronal excitability, seizure susceptibility and synaptic plasticity. [affinage.wi.mit.edu](https://affinage.wi.mit.edu/gene/CLPTM1?utm_source=chatgpt.com)

## 2. Human disease association: epilepsy

The most important publication is:

**Liu et al., 2023. De novo CLPTM1 variants with reduced GABA\(_A\)R current response in patients with epilepsy. Epilepsia.**

[Original publication (PubMed)](https://pubmed.ncbi.nlm.nih.gov/37577761/?utm_source=chatgpt.com)

The authors identified two unrelated individuals with de novo missense variants:

| Variant | Clinical presentation | Functional findings |
|---|---|---|
| c.1361G>A, p.Arg454His (R454H) | Infantile-onset generalized tonic-clonic seizures | Reduced GABA\(_A\) receptor current amplitude and altered receptor kinetics |
| c.1703G>A, p.Arg568Gln (R568Q) | Early-onset epilepsy, developmental impairment and severe neurological phenotype | Reduced GABA\(_A\) receptor currents and reduced surface expression of the GABA\(_A\)R γ2 subunit |

Some important qualifications:

- Both variants were confirmed to be de novo.
- Both showed functional effects in heterologous cell-based electrophysiological experiments.
- The first patient also carried a KCNQ2 variant (p.Pro29Ser), which complicates attribution of the epilepsy phenotype.
- The second patient had a much more severe neurological presentation, including developmental impairment and structural brain abnormalities.

The authors proposed that CLPTM1 dysfunction could contribute to epilepsy through impaired GABAergic inhibition.

**My interpretation:** This is credible candidate-gene evidence, but two individuals from a single publication are insufficient to establish a definitive monogenic epilepsy association.

## 3. Evidence from animal models

An interesting follow-up study was published in 2024:

**Ge & Craig, 2024. Haploinsufficiency of GABA\(_A\) Receptor-Associated Clptm1 Enhances Phasic and Tonic Inhibitory Neurotransmission, Suppresses Excitatory Synaptic Plasticity, and Impairs Memory. Journal of Neuroscience.**

[Original publication (PubMed)](https://pubmed.ncbi.nlm.nih.gov/38942471/?utm_source=chatgpt.com)

The authors generated Clptm1 knockout mice and demonstrated that heterozygous animals exhibited:

- Increased phasic and tonic inhibitory neurotransmission.
- Impaired hippocampal long-term potentiation (LTP).
- Impaired contextual fear memory.
- Rescue of LTP and memory phenotypes through pharmacological modulation of extrasynaptic GABA\(_A\) receptors containing the α5 subunit.

This is particularly interesting because it provides experimental evidence that **CLPTM1 haploinsufficiency can produce neurological and cognitive phenotypes in vivo**.

However, the mouse phenotype does not establish that human heterozygous loss-of-function variants cause a corresponding developmental disorder.

## 4. Cleft lip and palate: why the gene was originally identified

CLPTM1 was originally identified in 1998 in a family with cleft lip and palate.

The family carried a balanced chromosomal translocation:

`t(2;19)(q11.2;q13.3)`

The translocation disrupted CLPTM1.

However, subsequent analysis of 74 unrelated individuals with cleft lip and/or palate did not identify a significant association between CLPTM1 variants and the phenotype.

Consequently, the authors concluded that CLPTM1 was unlikely to be a major contributor to craniofacial abnormalities.

Reference:

[Yoshiura et al., 1998 (PubMed)](https://pubmed.ncbi.nlm.nih.gov/9828125/?utm_source=chatgpt.com)

This is an interesting historical observation, but there is no convincing evidence that CLPTM1 is an established cleft lip/palate disease gene.

## 5. Current gene–disease validity

This is where the distinction between biological plausibility and clinical validity becomes important.

The available gene-disease resources indicate:

| Resource | CLPTM1 status |
|---|---|
| OMIM | Gene entry exists, but no established morbid phenotype association |
| ClinGen | No established gene–disease relationship |
| Gene2Phenotype | No established disease association |
| DECIPHER | No curated gene–disease association |
| Published human evidence | Two individuals with de novo missense variants and epilepsy |
| Animal models | Evidence for neurological and cognitive consequences of haploinsufficiency |

Sources:
- [DECIPHER CLPTM1 clinical information](https://www.deciphergenomics.org/gene/CLPTM1/overview/clinical-info?utm_source=chatgpt.com)
- [NCBI Gene / Genetic Testing Registry](https://www.ncbi.nlm.nih.gov/gtr/genes/1209/?utm_source=chatgpt.com)

One additional observation: CLPTM1 has a relatively high predicted loss-of-function intolerance (pLI approximately 1.0; LOEUF 0.40 in the DECIPHER data).

This supports the possibility that the gene is dosage-sensitive, but constraint metrics alone cannot establish a disease mechanism or inheritance pattern.

## 6. Important distinction: CLPTM1 versus CLPTM1L

These are different genes:

| Feature | CLPTM1 | CLPTM1L |
|---|---|---|
| Chromosome | 19q13.32 | 5p15.33 |
| Main biological context | GABA receptor trafficking | ER membrane biology, lipid scramblase |
| Neurological disease evidence | Preliminary epilepsy association | No established Mendelian neurological disorder |
| Cancer susceptibility | Investigated in cancer studies | Well-known cancer susceptibility GWAS locus |

The similar names can cause confusion in automated gene–disease annotation.

---

## 7. Overall assessment

My assessment of CLPTM1 as a potential Mendelian disease gene:

| Evidence category | Assessment |
|---|---|
| Biological plausibility | Strong |
| Human genetic evidence | Preliminary |
| Functional evidence | Moderate |
| Animal model evidence | Supportive |
| Independent replication | Insufficient |
| Established Mendelian disease | No |
| Clinical diagnostic validity | Not established |

### Implications for variant interpretation

If I encountered a rare CLPTM1 variant during exome or genome analysis, I would pay particular attention to:

1. **Variant position:** Especially variants affecting conserved residues or regions relevant to GABA\(_A\) receptor interactions.
2. **Inheritance:** De novo variants would be particularly interesting given the published cases.
3. **Variant mechanism:** Do not automatically assume that loss-of-function variants and missense variants have equivalent effects. The available human evidence concerns missense variants.
4. **Phenotype:** Early-onset epilepsy, developmental delay, intellectual disability and potentially cognitive impairment would warrant investigation.
5. **Functional evidence:** Electrophysiological assays measuring GABA\(_A\) receptor currents could be particularly informative.

### My bottom line

I would classify **CLPTM1 as a promising candidate disease gene for an epilepsy/neurodevelopmental phenotype, rather than an established Mendelian disease gene**.

The combination of two de novo human variants with functional effects and the 2024 haploinsufficiency mouse model makes this gene worth investigating.

However, independent human cases, segregation evidence and better-defined genotype–phenotype correlations are still needed before assigning a definitive disease association.